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Background: Amenorrhea is defined as the cessation of menses. Hormone therapy is the most common treatment.
Due to the contraindications and side effects of it and the increasing demand for alternative medicine substitutes,
Mentha longifolia L. was used in this study. Mentha longifolia L. is a known medication in Iranian traditional
medicine to induce menstrual bleeding in women with secondary amenorrhea and oligomenorrhea.
Methods: A double-blind, randomized, placebo-controlled, multicenter study was conducted in 120 women with
secondary amenorrhea and oligomenorrhea. Treatment consisted of sequential oral syrup, 45 ml (15 ml three times
a day) for 2 weeks. If the patients did not have menstruation after 2 weeks of taking the medication, we would wait
for two more weeks. If the patients had menstruation at each stage of using the drug, we started it one week after
the end of menstruation. But if the patients had not menstruate after four weeks (two-week using of drug and
waiting for two more weeks), the previous steps were repeated. The drug and placebo were repeated in three
cycles of menstruation. Bleeding was documented by the patient on diary cards. The primary outcome variable was
the occurrence (yes/no) of bleeding during the first treatment cycle. The secondary efficacy outcome was the
regularity of bleeding pattern during the three cycles of the study.
Results: The number of women with bleeding during the first cycle were higher in the drug group as in the
placebo group (68.3% vs. 13.6%; p < 0.001). The regularity of bleeding throughout the study was markedly better in
the drug group compared with those given placebo (33.3% vs. 3.3%; p < 0.001). No notable complication or side
effect was reported in relation to Mentha longifolia L. syrup.
Conclusion: In conclusion, Mentha longifolia L. syrup is a safe, well-tolerated, and effective choice in inducing
bleeding and maintaining regular bleeding in women with secondary amenorrhea and oligomenorrhea.
Keywords: Mentha longifolia, Lamiacea, Amenorrhea, Oligomenorrhea, Iranian traditional medicine, Ehtebas tamsIntroduction
Secondary amenorrhea (SA) is defined as the cessation
of menses for 6 months in female previously irregular
menstrual pattern, or the cessation of menses for 3 con-
secutive months [1]. It has, on the other hand, been spe-
cifically defined in various ways, some of which overlap
with oligomenorrhea (infrequent menstrual flow at* Correspondence: nafiseh_zafar@yahoo.com
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[2,3]. The overall prevalence of secondary amenorrhea in
among women of reproductive age is around 3% [4] and
prevalence of oligomenorrhea is 10.2% [5].
The most common form of secondary amenorrhea is
hypogonadotrophic disorders caused by hypothalamic
suppression, particularly functional hypothalamic amen-
orrhea (FHA), due to various stressors with no evidence
of systemic/endocrine causal factors [6,7]. Another com-
mon form of secondary amenorrhea is ovulatory disor-
ders often associated with polycystic ovary syndromeCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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order in women [5,9].
Treatment of secondary amenorrhea and oligomenor-
rhea is mostly based on empiric hormone with estrogen
and progesterone [10]. Several complications have been
reported by hormone therapy [11].
One of the most influential Iranian physician between
9th and 14th centuries AD was Ibn –Sina or Avicenna
(980 – 1037 A.D). His chief medical book is “Al-Qanon
fi Al-Tibb” or “Canon of Medicine” [12,13]. The twenty-
first chapter of third book of “Canon of Medicine” deals
principally with various kinds of uterine diseases [14]. In
this section, amenorrhea and oligomenorrhea is described
under a same title: “Ehtebas Tams” [15]. “Ehtebas tams” is
defined as the absence of menstruation [14,16].
Based on Iranian traditional medicine (ITM) texts par-
ticularly “Canon of medicine” and “Al-Havi” (Rhazes
865–925 A.D), Mentha longifolia is one of the medicinal
herbs that can influence menstrual periods [14,17].
Mentha longifolia (L.) a member of the Lamiacea
(Labiatae) family, whose habitat is from Southeast Asia
and is known as Horse mint or wild mint [18]. The his-
torical use of it is not different from its use in modern
herbal medicine. It has been reported as a remedy for
common cold, cough, sinusitis, fever, bronchitis, indiges-
tion, intestinal colic, loss of appetite, nausea and vomit-
ing also it has other various uses in ITM that are
unknown in modern medicine like its indication for
menstrual disorders. Mentha longifolia known as Fuda-
naj or Pooneh in ITM is a common constituent of the
Middle East diet [19]. However, its effect on menstru-
ation has not been scientifically evaluated yet.
The aim of the present study is to compare the efficacy
of sequential Mentha longifolia syrup with that of pla-
cebo in inducing regular bleeding in women with sec-
ondary amenorrhea or oligomenorrhea and normal FSH,
TSH, Prolactin levels.
This is the first double-blind, placebo-controlled, ran-
domized study to assess Mentha longifolia syrup induced
bleeding in this specific diseased condition.Materials and methods
Patients
This multicenter double-blind, randomized study (6 cen-
ters in Tehran and Qom, Iran) was carried out among
120 women with secondary amenorrhea or oligomenor-
rhea (cessation of bleeding for at least 60 days without
pregnancy).
The patients were between 18 and 35 years old and
had premenopausal levels of follicle-stimulating hor-
mone (FSH) (<20 IU/l). Patients with abnormal prolac-
tine, abnormal thyroid function tests, and congenital
adrenal hyperplasia were excluded. Other exclusioncriteria included clinically significant diseases that might
have limited participation in or completion of the study
including any anatomical abnormality or gynaecological
neoplasia, a positive pregnancy test, breastfeeding, severe
drug allergy or history of severe unusual drug reactions
towards herbs and intake of any hormonal products
(chemical or herbal) in the previous 2 months.
All patients provided written informed consent. The
Ethics Committee of Shahed University approved the
protocol (approval number: 4/112251). Further, the trial
was registered in the Iranian Registry of Clinical Trials
with the number IRCT201110027690 N1.Preparations of Mentha longifolia L
Mentha longifolia L. dried leaves were purchased from
local market in Tehran bazar, the center of Tehran prov-
ince, Iran and identified by professor Gholamreza Amin,
and kept at the herbarium of faculty of pharmacy,
Tehran University of Medicinal Sciences, under the vou-
cher number PMP - 308.Volatile analysis of Mentha longifolia L
The dried plant were used for extraction of total essen-
tial oil using Clevenger apparatus and yielded 1 ml/
100 mg of dried plant. Analysis of total essential oil
showed some major component as; 1, 8 cineole
(11.58%), pulegone (21.90%), piperitone oxide (42.51%)
and caryophyllene oxide (3.64%).Preparations of syrup and placebo
Total evaporated etanolic extract of Mentha longifolia L.
used for preparation of syrup under supervision of pro-
fessor Kamalinejad at traditional pharmacy department
of faculty of traditional medicine, Tehran University of
Medicinal Sciences, Tehran- Iran while each 5 ml of
syrup contains 300 mg ethanol extract of plant dried
powder in the base of sucrose pharmacopoeal syrup.
The placebo was prepared in the same appearance,
with the base of sucrose pharmacopoeal syrup without
Mentha longifolia L. extract.Biochemical examinations
Blood samples were taken from all patients for evalu-
ation of the hormonal status including total testosterone,
free testosterone and FSH, LH, TSH and prolactin serum
levels. The blood samples (10 mL) were collected from
each of the patients after a 12 h overnight fasting. The
serum was separated by centrifugation at 3000 rpm for
10 min after keeping at room temperature for 15 min
and were measured by using the Roch diagnosticsW
chemiluminescence Immunoassay (CIA) analyzer.
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The patients were randomized in two groups (Drug or
placebo) to receive sequential oral syrup 45 ml three
times a day for 2 weeks. In the event of no menstrua-
tion in two weeks, the patient was given the medication
for two more weeks. After four weeks of having
no menstruation, the patient was instructed to take
her medication for extra two weeks and repeated the
previous steps.
In the event of bleeding in each stage of therapy, the
patient continued taking the medication one week after
the end of menstruation and restart it again.
The drug and placebo intake were repeated in three
cycles of menstruation (Figure 1). Then the patients had
to report any signs of bleeding immediately.
Randomization was affected in a double blind fashion;
patients received either mint or placebo according to
the code provided (in blocks of four at a ratio of 1:1) by
the traditional pharmacy department of the Tehran
University. The randomization code was not decoded
until after the last patient completed all the experi-
mental processes.
Physical and gynaecological examinations, ultrasound
scan of uterus and ovaries, and measurement of labora-
tory parameters (pregnancy test, blood chemistry, and
blood levels of FSH, LH, TSH, Prolactin, total Testoster-
one and free Testosterone) were performed at the begin-
ning of study. Demographic and baseline data, medical
history and any concomitant medications were also
recorded. On the day of randomization, the patients
were given a diary cards to complete during cycles 1 to
3 and were instructed on the correctly document drug











after one week of 
ending the 
bleeding
using the placebo 
or mint for two 
weeks more
Figure 1 Methods of use of mint or placebo in the study.of medications. Ultrasound scan of uterus and ovaries
and measurement of plasma hormonal levels (LH, FSH,
Total Testosterone and free Testosterone) were repeated
at the end of the study. Recording of concomitant medi-
cation, compliance and any adverse events were per-
formed at each visit. Pregnancy test was carried out with
any delay menstruation at each stage of the study.Statistical analyses
The primary outcome measure was the occurrence (yes/
no) of bleeding during the first treatment cycle. A bleed-
ing episode was defined as bleeding if it occurred after
consumption of medicinal herb.
Sample size was determined as follows. Based on
Altman nomogram when the level of significance was
α = 0.05 and the power to 80% and SD = 0.7, the number
of patients required to complete each treatment arm was
30 to 35. Taking into account an expected dropout rate
of 25%, the total number of patients required to investi-
gate the primary efficacy variable was 84. In addition, in
order to gain an insight into the regularity of bleeding in
the cycles following one cycle bleeding, it was decided to
recruit 120 patients.
The intention-to-treat (ITT) population used in the
analysis of the primary endpoint comprised all rando-
mized patients; those with missing diaries or missing
data were considered as ‘failures’.
The secondary efficacy variable was the regularity of
bleeding pattern during the three cycles of the study.
The ITT population for this analysis included all ran-
domized patients who had documented data in the diary
for three cycles (drug intake and bleeding data). The re-
gularity of bleeding was scored by an index for each
cycle as follows: an index of zero if no bleeding episode
occurred, index of 1 if only one bleeding episode oc-
curred, index of 2 if two times bleeding episode occurred
and index of 3 if bleeding occurred in three consecutive
cycles. The indices of all cycles were added together,
resulting in a score ranging from 0 (absence of bleeding)
to 3 (regular bleeding during all three cycles). These re-
gularity scores were compared between groups using the
Chi square test.
Further exploratory analyses were performed to com-
pare the effects of mint and placebo on hormonal
plasma levels, to determine the effects of stratification
by “PCOS and FHA” and “secondary” amenorrhea and
oligomenorrhea to evaluate any correlation between
bleeding pattern and “PCOS and FHA” and”“secondary
amenorrhea and oligomenorrhea”. The basis of these
evaluations was the ITT population.
Comparisons between two groups were carried out by
the student t-test and by the Chi square in the case of
categorical data.
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two-sided and a result with a p value of <0.05 was
explained as significant. However due to multiple testing,
the p values cannot be interpreted in a confirmatory sense
as can the outcome for the primary efficacy variable.
All randomized women who received at least one dose
of study drug were included in the safety analysis. Safety
parameters included adverse events, physical examin-
ation findings, body weight, ultrasound scan of uterus
and ovaries, concomitant medication, laboratory tests.Results
Initially 208 patients were interviewed from which 120
patients were recruited and randomized in two groups
of 60 patients. The distribution of patients during the
study is shown in Figure 2.
The baseline and demographic characteristics of these
patients are shown in Table 1; there were no relevant
differences between the groups. 45 patients in the mint
group and 34 patients in the placebo group completed
the study. The subjects who had discontinued their ther-
apy were higher in the placebo group (n = 26, 43.3%)
than the mint group (n = 15; 25%; P < 0.05). The main
reason of dropping out of the study was due to lack of





Allocated to mint group (n=60)
-Recevied mint (n=60)
-Did not receivemint (n=0)
Ending cycle 2 (n=52)
-Lost to follow-up (dueto personal
reasons) (n=7)
-Discontinued intervention (n=1)
Ending cycle 3 (n=45)
-Lost to follow-up (due to personal
reasons) (n=6)
-Discontinued intervention (n=1)
Figure 2 Distribution of patients.All 120 patients were included in the ITT analysis of
the primary efficacy variable and in the safety analyses
(Figure 1).
Bleeding patterns
The number of women with bleeding during the first
cycle of treatment (the primary outcome) was higher in
the mint group compared with the placebo group (68.3%
vs. 13.6%; p < 0.001). Therefore the mint treatment was
considered as more effective than placebo with regard to
the primary efficacy variable (Figure 3).
During the three cycles of treatment, the percentage of
patients who experienced bleeding episodes of any cycles
was considerably higher with mint than with placebo
(Figure 3). In both groups, on the other hand, the inci-
dence of bleeding was dominantly high in the first cycle
of treatment.
The regularity of bleeding (regularity score) was sig-
nificantly more consistent in patients treated with mint
than in those given placebo (Table 2). In the mint group,
44 patients (73.3%) had regularity score of >0 compared
with 18 patients (30%) in the placebo group (p < 0. 001)
(Table 2). Regular bleeding in all three cycles (the sec-
ondary efficacy) was achieved in 33.3% (n = 20) of mint-
treated patients but in placebo-treated patients only






-Not meeting inclusion criteria
(n=81)
-declined to participate (n=7)
Allocated to placebo group (n=60)
-Received placebo (n=59)
-Did not receive placebo (n=1)
Ending cycle 2 (n=46)
-Lost to follow-up (due to personal
reasons)n=6)
-Discontinued intervention (n=7)
Ending cycle 3 (n=34)
-Lost to follow-up (due to personal
reasons) (n=3)
-Discontinued intervention (n=9)
Table 1 Demographic and baseline characteristics
Mint Placebo P value Statistical
(n = 60) (n = 60) test
Age (years), mean ± SD 24.63 ± 5.74 26.10 ± 5.71 0.1 T test
Weight (kg), mean ± SD 66.20 ± 16.70 66.97 ± 15.29 0.7 T test
Height (cm), mean ± SD 159.86 ± 6.3 161.15 ± 5.7 0.2 T test
BMI (kg/m2) 25.82 ± 5.93 25.80 ± 5.83 0.9 T test
PCOS, n (%) 44(73.3%) 49(81.7%) 0.1 Chi square
FHA, n (%) 16(26.7%) 11(18.3%) 0.1 Chi square
Secondary Amenorrhea, n (%) 45(75%) 40(66.7%) 0.2 Chi square
Oligomenorrhea, n (%) 15(25%) 20(33.3%) 0.2 Chi square
P value > 0.05.
SD, standard deviation; BMI, Body Mass Index; PCOS, Poly Cystic Ovarian Syndrome; FHA, Functional Hypothalamic Amenorrhea.
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mint or placebo (intention-to-treat population; n = 120)
is shown in Table 2.
Hormonal parameters
At the end of the treatment, there was a significant de-
crease in luteinizing hormone (LH) in mint group com-
pared to placebo group (p < 0.002).
No changes of total testosterone, free testosterone and
follicle-stimulating hormone (FSH) levels in the mint-
treated group nor any changes of hormonal parameters
in placebo group was recorded (Table 3).
Subgroups analyses
Comparing the subgroups of patients with PCOS (n = 93)
and FHA (n = 27) with respect to demographic parametersFigure 3 Percentage of patients with bleeding episodes per
cycle during treatment with mint (n=60) or placebo (n=60)
(Intention-to-treat (ITT) population).revealed significantly (p < 0.001) more patients in the
PCOS subgroup than in the FHA subgroup (Table 1).
The subgroups of patients with PCOS and FHA, the inci-
dence of bleeding during the first cycle (37.6% vs. 51.9%;
p = 0.378) and regular bleeding in all three cycles (15.1%
vs. 29.6%; p = 0.096) was not significantly different.
The subgroups of patients with secondary amenorrhea
(n = 85) and oligomenorrhea (n = 35) showed signifi-
cantly (p < 0.001) more in the secondary amenorrhea
subgroup than in the oligomenorrhea subgroup (Table 1).
Among subgroups of secondary amenorrhea and oligo-
menorrhea, the incidence of bleeding during the first
cycle (40% vs. 42.9%; respectively p = 0.27) and regular
bleeding in all three cycles (16.5% vs. 22.9%; respectively
p = 0.442) was not significantly different.
There were no other significant differences between
the four subgroups with regard to demographic and
other baseline characteristics.Safety and tolerability
Mint syrup was well tolerated by the patients. There
were no serious adverse reactions in the mint group.
Complication were classified as pleasant or unpleasant
and were reported in 19 patients (31.7%) treated with
mint syrup. The most common unpleasant reports
were spotting (n = 7), severe bleeding (n = 2), constipa-
tion (n = 1) and stomachache (n = 1) were seen in the
mint-treated group.
The most common pleasant effects were reduced
gastrointestinal complaints such as reduced bloating
(n = 2), abdominal cramps (n = 1), nausea (n = 1), stoma-
chache (n = 1). Another good side effect was decreasing
dysmenorrhea (n = 2).Discussion
The present study is the first comprehensive assessment
of menstruation upon Mentha longifolia L. ingestion in
Table 2 Regularity score by number of patients during treatment with mint or placebo (intention-to-treat population;
n = 120)
Menstruations Score 0 1 2 3 P value of Chi square
Mint, n (%) 16 (26.7%) 13 (21.7%) 11 (18.3%) 20 (33.3%) <0.001
Placebo, n (%) 42 (70%) 15 (25%) 1 (1.7%) 2 (3.3%)
p < 0. 001.
Data are expressed as n (%), where n is number of patients.
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in women with secondary amenorrhea and oligomenorrhea.
The results from this study showed that sequential
mint intake has statistically significant advantages over
placebo with regard to the induction of uterus bleeding
and the regularity of the menstruation.
The percentage of patients experiencing uterus bleed-
ing during the first cycle was 68.3% in the mint group
and 13.6% in the placebo group. The percentage of
patients with bleeding was highest during the first cycle
and tended to reduce thereafter in both groups.
The regularity of bleeding throughout the study was
markedly improved in the mint group. Regular bleeding
during three cycles was achieved in one third of the
patients treated with mint compared to those given pla-
cebo (33.3% vs 3.3%).
To our knowledge no study has been performed yet to
evaluate the effects of this herbal drug on uterusFigure 4 Percentage of patients with regular bleeding in all three cyc
(secondary efficacy variable).bleeding. Due to the lack of similar studies with herbal
remedies, the results of other studies are reviewed.
In a study by Panay et al. on 104 patient to assess the
efficacy of dydrogesterone in inducing regular with-
drawal bleeding, the number of women with withdrawal
bleeding during the first cycle was twice as high in the
dydrogesterone group as in the placebo group (65.4% vs.
30.8%; p < 0.0004). Superiority of dydrogesterone was
also observed for regularity of bleeding over the six
cycles (p < 0.0001) [2].
In Dessole et Al. studied, they used a low dose
(75 IU/day for 5 days) of purified FSH (Metrodin) in
10 oligomenorrheic patients (aged 18–30) for 25 cycles.
The onset of menstruation occurred in 7 patients (70%)
and in 19 treatment cycles (76%), the ovulation was veri-
fied in 5 of these patients (50%) for 13 cycles (52%). One
patient had spotting after the treatment, two patients did
not have any response [20].les during treatment with mint (n=45) or placebo (n=34)
Table 3 Pre- and post-treatment TT, FT, LH, FSH
variables Group Pre-treatment P value of T test Post-treatment P value of T test
TT (ng/mL) Mint 0.7 ± 0.28 0.2 0.51 ± 0.29 0.2
Placebo 2.01 ± 8.8 0.65 ± 0.59
FT (ng/mL) Mint 1.68 ± 1.12 0.8 1.35 ± 0.94 0.3
Placebo 1.65 ± 1.15 1.62 ± 1.28
LH (mlU/mL) Mint 8.9 ± 7.4 0.2 5.6 ± 4.6 0.002
Placebo 10.5 ± 6.4 10.9 ± 5.8
FSH (mlU/mL) Mint 6.65 ± 11.8 0.4 4.62 ± 1.68 0.9
Placebo 5.3 ± 2.03 4.6 ± 1.1
TT, total testosterone; FT, free testosterone; LH, Luteinizing hormone; FSH, follicle-stimulating hormone.
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longifolia L. syrup will decrease LH levels. In a study by
Shariati M et al., the effect of Lamiacea family on FSH
was investigated. Assessment of the effect of Mentha
pulegium leaves on gonadotropin tests in male rat
showed that the hydro-alcoholic extract of Mentha pule-
gium leaves causes a significant decrease in FSH and LH
levels [21].
In contrast, another experimental study by Akdogan
M et al. on effects of Mentha piperita and Mentha spi-
cata on plasma androgen and FSH and LH levels, it was
reported that the consumption of M. piperita and M.
spicata can decreased plasma testosterone and increase
the plasma LH and FSH levels in rats [22]. Because anti-
androgenic effects of spearmint and peppermint were
found in rats, they observed the effect of this herbal tea
on the androgen levels in hirsute women so Akdogan M
et al., choose twenty-one female hirsute patients, were
took a cup of herbal tea which was steeped with M. spi-
cata for 5 days twice a day in the follicular phase of their
menstrual cycles. After treatment with spearmint teas,
there was a significant decrease in free testosterone and
increase in LH and FSH levels. There were no significant
decreases in total testosterone [23].
The dropout rate in the placebo group (n = 26, 43/3%)
were higher than the treatment group (n = 15; 25%;
P < 0.05). Total dropout is more than other studies.
We need to notice some limitations that we have face
in present study. These limitations are generally com-
mon in studies involving human subjects. First, the
dropout rate in this study was more than usual, due to
the long duration of treatment and interference with
personal and cultural issues. Second, the Iranian trad-
itional medicine have one major variable which be
present in human including temperament (mezaj) and
racial/ethnic, sex, age, area, season, job and etc. [14,24].
These variations can effect in bioavailability differences
in human. Indeed in this study our subjects were unable
to assess individual differences in patients according to
traditional medicine.Conclusion
The results of this study showed that Mentha longifolia
L. syrup is significantly effective over placebo in inducing
bleeding in women with secondary amenorrhea and that
the pattern of bleeding is significantly more regular with
Mentha longifolia L., while side effects are least.
Due to the beneficial effects of Mentha longifolia L.,
besides its safety, availability and low cost; a future
therapeutic role in women with amenorrhea and oligo-
menorrhea is expected.
However, further large randomized studies are needed
to determine appropriate dosages and duration of treat-
ment and the reliability of Mentha longifolia L. as a good
option for cessation of menstruation.Abbreviations
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